Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (NCT05256225)
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
🩺 Plain-English Summary (8th-Grade Level)
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (414 Sites)
Showing the first 25 of 414 sites.
- University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Alaska Women's Cancer Care — Anchorage, Alaska
- Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Sutter Auburn Faith Hospital — Auburn, California
- Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- John Muir Medical Center-Concord — Concord, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- City of Hope Seacliff — Huntington Beach, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- City of Hope at Irvine Lennar — Irvine, California
- Kaiser Permanente-Irvine — Irvine, California
- City of Hope at Long Beach Elm — Long Beach, California
- Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
- Memorial Medical Center — Modesto, California
- Palo Alto Medical Foundation-Gynecologic Oncology — Mountain View, California
- Saint Joseph Hospital - Orange — Orange, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- Stanford Cancer Institute Palo Alto — Palo Alto, California
- Kaiser Permanente - Panorama City — Panorama City, California
- Kaiser Permanente-Riverside — Riverside, California
- Sutter Roseville Medical Center — Roseville, California
- Sutter Medical Center Sacramento — Sacramento, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Endometrial Carcinoma
- A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma — New Haven, Connecticut
- Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors — Houston, Texas
- Targeting Inflammation for Endometrial Cancer Prevention — Scottsdale, Arizona
- Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain — Jacksonville, Florida
- Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding — Scottsdale, Arizona
- Screening and Staging of Benign vs Malignant Pelvic Abnormalities — Rochester, Minnesota
Explore by condition: All Endometrial Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.